Timely Peer Education to Overcome Clinical Hesitation in Rare Oncology

Therapy Area:

Rare / Genetic Disease

Product Stage:

Post-launch

Company Type:

Top 10 global pharmaceutical company

Location:

North America & Asia-Pacific

The challenge

Despite a promising clinical profile, a newly launched rare oncology therapy was seeing slow uptake among treating HCPs. Efficacy was not the barrier. Clinical hesitation was. The biomarker was rare, and its placement and clinical utility were presented inconsistently in lab reports, often beyond the first page. This reduced its visibility and perceived actionability, making timely clinical decisions and appropriate prescribing less likely.

Reinforced clinical hesitation, reduced prescriber confidence, and put the therapy’s launch success at risk, with direct implications for patient access and revenue forecasts.

Key Issues

Education delivered months before launch was not retained or recalled when prescribing decisions were being made, slowing physician adoption, reinforcing hesitation and slowing launch progress

The solution

We deployed Expert Exchange, our peer-to-peer education platform that connects practicing experts directly with treating HCPs.

Activated within 48 hours of a of an actionable biomarker result being reported
Delivered non-promotional, expert-led sessions tailored to HCP clinical questions
Helped treating HCPs navigate biomarker and diagnostic questions, strengthening the link between diagnosis and treatment and building prescriber confidence
Integrated real-world lab data to target HCPs at the moment of decision-making

RESULTS

The initiative delivered measurable improvements in HCP engagement, diagnostic understanding, and therapy adoption, directly impacting clinical behavior and patient access. HCPs reported greater confidence in diagnostic interpretation and a shorter time between education and clinical action.

Key outcomes included:

86% HCP engagement rate, doubling industry benchmarks
89% of participating HCPs reported increased understanding of the diagnostic pathway

Testimonial

“Expert Exchange gave our field teams a credible way to engage physicians. The shift from promotional messaging to peer-led education created a more receptive environment for early adoption. By the time our reps reached out, HCPs were already informed and open to the conversation – setting a clear pathway to success for our field force.”

About Diaceutics

At Diaceutics, our vision is Precision for All: a future where every eligible patient is identified, diagnosed and receives the right therapy at the right time.

For more than 20 years, we have helped biopharma companies overcome the diagnostic and commercialization barriers that stand between scientific innovation and patient impact. Today, we combine diagnostic intelligence, expert insight and targeted engagement to unlock the full potential of diagnostic-driven therapies—and more life for the patients they are designed to serve.